Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients

European Journal of Clinical Pharmacology

Volumn 63, Issue 5, 2007, Pages 479-483

  Sriwiriyajan, Somchai ^a   Mahatthanatrakul, Werawath ^a   Ridtitid, Wibool ^a   Jaruratanasirikul, Sutep ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Drug interaction; Efavirenz; HIV infected patients; Ketoconazole; Pharmacokinetics

Indexed keywords

EFAVIRENZ; KETOCONAZOLE; LAMIVUDINE; STAVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BENZOXAZINES; CANDIDIASIS, ORAL; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMANS; KETOCONAZOLE; LAMIVUDINE; MALE; MIDDLE AGED; STAVUDINE;

EID: 34147124260     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0282-8     Document Type: Article

References (19)

1. Department of Health and Human Services (2006) Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents-October 10, 2006. http://www.aidsinfo.nih.gov. Assessed December 20, 2006
2. Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, Avery GS (1982) Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23:1-36
3. Adkins JC, Noble S (1998) Efavirenz. Drugs 56:1055-1064
4. Yuen KH, Peh KK (1998) Simple high-performance liquid chromatographic method for determination of ketoconazole in human ploasma. J Chromatogr B 715:436-440
5. Ellepola AN, Samaranayake LP (2000) Oral candidal infections and antimycotics. Crit Rev Oral Biol Med 11:172-198
6. Thai Ministry of Public Health (2002) National guidelines for the clinical management of HIV infection in children and adults, 7th edn. Garnsadsana, Bangkok
7. Teanpaisan R, Nittayananta W, Chongsuvivatwong V (2000) Biotypes of oral Candida albicans isolated from AIDS patients and HIV-free subjects in Thailand. J Oral Pathol Med 29:193-199
8. Van Roey J, Haxaire M, Kamya M, Lwanga I, Katabira E (2004) Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr 35:144-150
9. Gascoigne EW, Barton GJ, Michaels M, Meuldermans WH (1981) The kinetics of ketoconazole in animals and man. Clin Res Rev 1:177-187
10. Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA (1982) Disposition of ketoconazole, an oral antifungal, in human. Antimicrob Agents Chemother 21:151-158
11. Lamson M, Robinson P, Gigliotti M, Myers WM (1998) The pharmacokinetic interaction of nevirapine and ketoconazole. In: Abstr 12th World AIDS Conf, abstr 12218. Geneva, p 55
12. Berry M, Mulcahy F, Merry C, Gibbons S, Back D (1999) Pharmacokinetics and potential interactions and amongst antiretroviral agents used to treat HIV infection. Clin Pharmacokinet 36:289-304
13. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbon SE, Berry MG, Back DJ (2001) The pharmacokinetics of methadone in HIVpositive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 51:213-217
14. Aarnoutse RE, Grintjes K, Telgt DS, Stek M Jr, Hugen PW, Reiss P, Koopmans PP, Hekster YA, Burger DM (2002) The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 71:57-67
15. Dailly E, Allavena C, Raffi F, Jolliet P (2005) Pharmacokinetic evidence of the induction of lopinavir metabolism by efavirenz. Br J Clin Pharmacol 60:32-34
16. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y, Aberg JA (2005) Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 39:307-312
17. Berruet N, Sentenac S, Auchere D, Gimenez F, Farinotti R, Fernandez C (2005) Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats. J Pharm Pharmaceut Sci 8:226-234
18. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkin PB (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in human. Clin Pharmacol Ther 72:1-9
19. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW (2002) Interaction of Common Azole Antifungals with Pglycoprotein. Antimicrob Agents Chemother 46:160-165